Supplementary Material 0114-5916/09/0007-0001/$49.95/0 REVIEW ARTICLE © 2009 Adis Data Information BV

Total Page:16

File Type:pdf, Size:1020Kb

Supplementary Material 0114-5916/09/0007-0001/$49.95/0 REVIEW ARTICLE © 2009 Adis Data Information BV Drug Safety 2009; 32 (7): Supplementary Material 0114-5916/09/0007-0001/$49.95/0 REVIEW ARTICLE © 2009 Adis Data Information BV. All rights reserved. Pharmacokinetic Changes of Psychotropic Drugs in Patients with Liver Disease Implications for Dose Adaptation Chantal Schlatter,† Sabin S. Egger,† Lydia Tchambaz† and Stephan Krähenbühl Division of Clinical Pharmacology & Toxicology, University Hospital, Basel, Switzerland † These authors contributed equally to this work. Supplementary Material This supplementary material contains the table referred to in the full version of this article, which can be found at http://drugsafety.adisonline.com. Note the reference citations and reference list are independent from the published article and reference numbering will differ. 1 Table I. Kinetic data including metabolic pathway, hepatic and dose-dependent adverse effects and dose adjustment recommendations for the use of psychotropic drugs in patients with liver disease b Drug Drug Metabolism Q0 t1/2 [h] PB Vd F [%] Clsys E Hepatic Dose-dependent Studies performed and dosage recom- cat.a [%] [L/kg] [L/h] adverse adverse reactions mendations effects Psychostimulants Am- Lo Deethylation 0.95 2 95 restlessness, dizzi- Studies: No clinical studies available in pa- fepramone of the amine ness, tremor, insom- tients with liver disease. Product information: function, nia, anxiety, delirium, Contraindicated in patients with liver failure. reduction of hallucinations, de- Personal recommendation: Should be the ketone pression, changes in avoided in patients with liver disease. function, libido, pallor or flush- and hy- ing, palpitation, ar- droxylation rhythmia, anginal pain, of the ben- hypertension, circula- zene ring[1-3] tory collapse, exces- sive sweating, dry mouth, anorexia[1] Methyl- Hi Deesterifi- 0.95 2 20 2 30 40 0.7 Case re- nervousness, insom- Studies: No clinical studies available in pa- phenidate cation by ports: nia, headache, dizzi- tients with liver disease. Product information: non micro- hepatocel- ness, dyskinesia, tics, No recommendations provided. Personal somal es- lular in- seizure, abdominal recommendation: According to pharmacoki- terase to jury,[4] liver pain, nausea, ano- netic data, start with a third of normal dose. ritalinic acid, failure after rexia, tachycardia, Adjust maintenance dose according to dose- minor: oxi- high palpitation, increased dependent adverse reactions. dation, hy- doses.[5] blood pressure, ar- droxyla- rhythmia, visual dis- tion.[2] turbances[1, 2, 6] Pharma- cokinetic data are presented as mean values for both enanti- omers of 2 b Drug Drug Metabolism Q0 t1/2 [h] PB Vd F [%] Clsys E Hepatic Dose-dependent Studies performed and dosage recom- cat.a [%] [L/kg] [L/h] adverse adverse reactions mendations effects methyl- phenidate. Modafinil[7] Lo Hydrolytic 0.95 10.5 62 0.9 40-65 3.4 0.06 Sporadic: headache, anxiety Studies: In an open-label study, 21 patients deamida- elevated nervousness, insom- with primary biliary cirrhosis received modaf- tion, S- liver en- nia, dizziness, nau- inil at an initial dose of 100mg/d for treatment oxidation, zymes, sea, diarrhoea, ano- of daytime somnolence and fatigue.[9] Dos- aromatic cholestatic rexia, dry mouth, con- age was up-titrated according to tolerability ring hy- liver injury[1, stipation, changes in and response. Significant reduction in day- droxylation, 3] blood pressure, extra- time somnolence and fatigue were observed. glucuronida- systoles, palpitations, Seven patients discontinued treatment due tion.[3] tachycardia, arrhyth- to significant headache. No major increase in mias[1, 8] blood pressure was observed. Product in- formation: Caution in patients with severe liver disease. T1/2 is doubled in patients with liver cirrhosis. 50% dose reduction in pa- tients with severe liver disease to 100- 200mg/d. Personal recommendation: Ac- cording to pharmacokinetic data, open-label study and product information, start with 100mg daily and adjust dosage according to dose-dependent adverse reactions. Phenter- Nk Mainly renal 0.3 20 3.5 restlessness, dizzi- Studies: No clinical studies available in pa- mine elimination, ness, tremor, insom- tients with liver insufficiency. Product infor- 5% metabo- nia, anxiety, hallucina- mation: Contraindicated in patients with liver lized by N- tions, changes in li- insufficiency. Personal recommendation: oxidation, bido, palpitation, ar- According to pharmacokinetic data showing entero- rhythmia, anginal pain, primarily renal elimination, dosage should be hepatic hypertension, circula- adjusted according to renal function. circulation[1] tory collapse, exces- sive sweating, dry mouth, gastrointestinal symptoms[1] 3 b Drug Drug Metabolism Q0 t1/2 [h] PB Vd F [%] Clsys E Hepatic Dose-dependent Studies performed and dosage recom- cat.a [%] [L/kg] [L/h] adverse adverse reactions mendations effects Phenylpro- Lo Renal elimi- 0.15 4 4 99 restlessness, dizzi- Studies: No clinical studies available in pa- panolamine nation[1] ness, tremor, insom- tients with liver disease. Product information: nia, anxiety, aggres- Contraindicated in patients with liver failure. siveness, irritability, Personal recommendation: According to changes in libido, pharmacokinetic data, showing primarily palpitation, tachycar- renal elimination, dosage should be adjusted dia, anginal pain, hy- according to renal function. pertension, excessive sweating, dry mouth, anorexia, gastrointes- tinal symptoms[1] Sibutramine Hi Demethyla- 1 1.1 97 1750 >0.9 frequency tachycardia, palpita- Studies: No clinical studies available in pa- tion (CYP unknown: tions, hypertension, tients with liver disease. Product information: 3A4) to abnormal constipation, anorexia, Combined AUC of the two active metabolites active liver func- nausea, dry mouth, increased by 24% in patients with moderate mono- tion tests insomnia, headache, liver insufficiency compared with healthy desmethyl- (ALT, AST, dizziness[1, 3, 10] subjects. No dosage adjustment necessary and di- AP);[3] case in patients with mild to moderate liver im- desmethyl- report: cho- pairment. Contraindicated in patients with sibutramine, lestatic severe liver dysfunction. Personal recom- followed by hepatitis.[11] mendation: According to pharmacokinetic hydroxyla- data, start with the lowest possible dose tion and available (10mg/d). Adjust maintenance conjuga- dose according to dose-dependent adverse tion,[1, 8] reactions. entero- hepatic circula- tion.[10] Antiepileptics 4 b Drug Drug Metabolism Q0 t1/2 [h] PB Vd F [%] Clsys E Hepatic Dose-dependent Studies performed and dosage recom- cat.a [%] [L/kg] [L/h] adverse adverse reactions mendations effects Barbexa- Lo Hydroxyla- 0.75 80 50 0.7 90 0.3 <0.01 Induction of Irritability, agitation, Studies: Mean t1/2 of phenobarbital was sig- clone tion to hy- acute in- drowsiness, optical nificantly prolonged by 51% in cirrhotics droxyphe- termittent hallucinations, ataxia, compared with healthy individuals (130 vs 86 [1] [13] nobarbital porphyria. nystagmus, dizziness, hours). T1/2 of phenobarbital was not sig- (inactive).[12] vomiting, weight loss, nificantly different between patients with Note: Bar- gingival hyperplasia, acute viral hepatitis and healthy individuals bexaclon is respiratory depres- (104 vs 86 hours).[13] Monitoring of serum a salt com- sion, hypotension, levels recommended in patients with liver posed of shock, rhabdomyoly- disease and prolonged therapy.[13] Product phenobarbi- sis[1] information: Contraindicated in patients with tal and L- severe liver disease. Adjust dosage in pa- propylhexe- tients with liver disease (no specification) drine. The and monitor serum levels. Personal recom- listed kinetic mendation: According to pharmacokinetic data refer to data, start with dose in the lower range of phenobarbi- normal. Adjust maintenance dose according tal. to the measured therapeutic concentration (therapeutic range: 10-40 mg/L). Car- Lo Epoxidation 1 15 75 1.4 >70 4.5 0.08 Frequent: dizziness, drowsiness, Studies: No clinical studies available in pa- bamazepine to active hepatocel- unsteadiness, head- tients with liver disease. Product information: epoxide lular injury ache, ataxia, diplopia, Caution in patients with liver disease. Moni- metabolite (increase of nausea, vomiting, tor liver function and stop carbamazepine in by CYP transami- asthenia, tremor, dy- case of worsening liver function. Personal 3A4, glu- nases). skinesia, oedemas, recommendation: According to pharmacoki- curonida- Rare: cho- weight gain, SIADH, netic data, start with initial dose in the lower tion, further lestatic liver tachycardia, hypoten- range of normal and adjust maintenance metabolism injury. Very sion, arrhythmia, res- dose according to plasma concentrations of of active rare: granu- piratory depression[1, 2, carbamazepine (therapeutic range: 4-11 metabolite lomas, liver 8] mg/L). by epoxide failure.[1, 4] hydrolase.[2] Induction of acute in- termittent porphyria.[1] 5 b Drug Drug Metabolism Q0 t1/2 [h] PB Vd F [%] Clsys E Hepatic Dose-dependent Studies performed and dosage recom- cat.a [%] [L/kg] [L/h] adverse adverse reactions mendations effects Clonaze- Lo CYP 3A4,[14] 1 30 85 3 98 6.5 0.12 Rare: hepa- drowsiness, dizziness, Studies: PB reduced in cirrhotic patients.[15] pam nitro-group tocellular muscular weakness, Patients with liver cirrhosis may be sensitive reduction, injury.[4] ataxia, dysarthria, to sedative effects of benzodiazepines.[16] N- constipation, coordina- Product information: Clonazepam should not acetyla- tion disturbances, be used in
Recommended publications
  • Use of Human Plasma Samples to Identify Circulating Drug Metabolites That Inhibit Cytochrome P450 Enzymes
    1521-009X/44/8/1217–1228$25.00 http://dx.doi.org/10.1124/dmd.116.071084 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:1217–1228, August 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes Heather Eng and R. Scott Obach Pfizer Inc., Groton, Connecticut Received April 19, 2016; accepted June 3, 2016 ABSTRACT Drug interactions elicited through inhibition of cytochrome P450 fractions were tested for inhibition of six human P450 enzyme (P450) enzymes are important in pharmacotherapy. Recently, activities (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and greater attention has been focused on not only parent drugs CYP3A4). Observation of inhibition in fractions that correspond to inhibiting P450 enzymes but also on possible inhibition of these the retention times of metabolites indicates that the metabolite Downloaded from enzymes by circulating metabolites. In this report, an ex vivo method has the potential to contribute to P450 inhibition in vivo. Using whereby the potential for circulating metabolites to be inhibitors of this approach, norfluoxetine, hydroxyitraconazole, desmethyldiltia- P450 enzymes is described. To test this method, seven drugs and zem, desacetyldiltiazem, desethylamiodarone, hydroxybupropion, their known plasma metabolites were added to control human erythro-dihydrobupropion, and threo-dihydrobupropion were iden- plasma at concentrations previously reported to occur in humans
    [Show full text]
  • Aerobic Treatment of Selective Serotonin Reuptake Inhibitors in Landfill Leachate Ove Bergersen1*, Kine Østnes Hanssen2 and Terje Vasskog2,3
    Bergersen et al. Environmental Sciences Europe (2015) 27:6 DOI 10.1186/s12302-014-0035-0 RESEARCH Open Access Aerobic treatment of selective serotonin reuptake inhibitors in landfill leachate Ove Bergersen1*, Kine Østnes Hanssen2 and Terje Vasskog2,3 Abstract Background: Pharmaceuticals used in human medical care are not completely eliminated in the human body and can enter the municipal sewage sludge system and leachate water from landfill both as the parent compound and as their biologically active metabolites. The selective serotonin reuptake inhibitors (SSRIs) have a large potential for unwanted effects on nontarget organisms in the environment. Leachates from active or old closed landfills are often treated with continuous stirring and simple aeration in a pond/lagoon before infiltration into the environment. The aim of this work was to simulate the reduction of five SSRIs (citalopram, fluoxetine, paroxetine, sertraline and fluvoxamine) and three of their metabolites (desmethylcitalopram, didesmethylcitalopram and norfluoxetine) during aerobic treatment of leachate from landfills. This landfill leachate-simulation experiment was performed to see what happens with the pharmaceuticals during aerated treatment and continuous stirring of landfill leachate for 120 h. It is important to establish whether different pollutants such as pharmaceuticals can be removed (oxidized or otherwise degraded) or not before infiltration into the environment. Results: All the SSRIs had a significant concentration reduction during the aeration treatment process. Total SSRI concentrations were reduced significantly during aerobic treatment, and the individual SSRIs were reduced by 89% to 100% after 120 h. Among the high-concentration samples, fluoxetine (10 mg L−1) was the least degraded with 93% concentration reduction.
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS
    Clinical, Forensic & Toxicology Article “The Big Pain”: Development of Pain-Free Methods for Analyzing 231 Multiclass Drugs and Metabolites by LC-MS/MS By Sharon Lupo As the use of prescription and nonprescription drugs grows, the need for fast, accurate, and comprehensive methods is also rapidly increasing. Historically, drug testing has focused on forensic applications such as cause of death determinations or the detection of drug use in specific populations (military, workplace, probation/parole, sports doping). However, modern drug testing has expanded well into the clinical arena with a growing list of target analytes and testing purposes. Clinicians often request the analysis of large panels of drugs and metabolites that can be used to ensure compliance with prescribed pain medication regimens and to detect abuse or diversion of medications. With prescription drug abuse reaching epidemic levels [1], demand is growing for analytical methods that can ensure accurate results for comprehensive drug lists with reasonable analysis times. LC-MS/MS is an excellent technique for this work because it offers greater sensitivity and specificity than immunoassay and—with a highly selective and retentive Raptor™ Biphenyl column—can provide definitive results for a wide range of compounds. Typically, forensic and pain management drug testing consists of an initial screening analysis, which is qualitative, quick, and requires only minimal sample preparation. Samples that test positive during screening are then subjected to a quantitative confirmatory analysis. Whereas screening assays may cover a broad list of compounds and are generally less sensitive and specific, confirmation testing provides fast, targeted analysis using chromatographic conditions that are optimized for specific panels.
    [Show full text]
  • Analytical Methods for Determination of Benzodiazepines. a Short Review
    Cent. Eur. J. Chem. • 12(10) • 2014 • 994-1007 DOI: 10.2478/s11532-014-0551-1 Central European Journal of Chemistry Analytical methods for determination of benzodiazepines. A short review Review Article Paulina Szatkowska1, Marcin Koba1*, Piotr Kośliński1, Jacek Wandas1, Tomasz Bączek2,3 1Department of Toxicology, Faculty of Pharmacy, Collegium Medicum of Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland 3Institute of Health Sciences, Division of Human Anatomy and Physiology, Pomeranian University of Słupsk, 76-200 Słupsk, Poland Received 16 July 2013; Accepted 6 February 2014 Abstract: Benzodiazepines (BDZs) are generally commonly used as anxiolytic and/or hypnotic drugs as a ligand of the GABAA-benzodiazepine receptor. Moreover, some of benzodiazepines are widely used as an anti-depressive and sedative drugs, and also as anti-epileptic drugs and in some cases can be useful as an adjunct treatment in refractory epilepsies or anti-alcoholic therapy. High-performance liquid chromatography (HPLC) methods, thin-layer chromatography (TLC) methods, gas chromatography (GC) methods, capillary electrophoresis (CE) methods and some of spectrophotometric and spectrofluorometric methods were developed and have been extensively applied to the analysis of number of benzodiazepine derivative drugs (BDZs) providing reliable and accurate results. The available chemical methods for the determination of BDZs in biological materials and pharmaceutical formulations are reviewed in this work. Keywords: Analytical methods • Benzodiazepines • Drugs analysis • Pharmaceutical formulations © Versita Sp. z o.o. 1. Introduction and long). For this reason, an application of these drugs became broader allowing their utility to a larger extent, Benzodiazepines have been first introduced into medical and at the same time, problems related to drug abuse practice in the 60s of the last century.
    [Show full text]
  • The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe
    EMBARGO — 7 JUNE 7. 6. 2018 UPDATED 11:30 Central European Time/CET (10:30 Western European Time/WET/Lisbon) Proof - 28 May 2018 not for circulation PERSPECTIVES ON DRUGS The misuse of benzodiazepines among high-risk opioid users in Europe Benzodiazepines are a widely prescribed I Introduction group of medicines with a range of clinical uses that include treating Benzodiazepines have a range of clinical uses and are among the most commonly prescribed medicines globally. anxiety, insomnia and managing alcohol They are useful in the short-term treatment of anxiety and withdrawal. This group of medicines is insomnia, and in managing alcohol withdrawal (Medicines often misused by high-risk opioid users, and Healthcare Products Regulatory Agency, 2015). Like all medicines, benzodiazepines can produce side effects. They and this is associated with considerable may also be misused, which we define as use without a morbidity and mortality. This paper prescription from a medical practitioner or, if prescribed, when describes the impact of benzodiazepines they are used outside accepted medical practice or guidelines. misuse on the health and treatment of While the misuse of benzodiazepines has been identified high-risk opioid users. as a concern for large groups in the general population, for example, among elderly people and women, this analysis focuses specifically on misuse among high-risk opioid users (1), a group of people among whom these medicines have been linked with severe treatment challenges and implicated in considerable numbers of drug-related deaths. It is important to stress that much benzodiazepine prescribing to high-risk drug users is done with legitimate therapeutic aims in mind.
    [Show full text]
  • Proposed Regulation of the State Board of Pharmacy
    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R150-16 Workshop September 8, 2016 Explanation – Language in blue italics is new; language in red text [omitted material] is language to be omitted, and language in green text indicates prior Board-approved amendments that are in the process of being codified. AUTHORITY: §1, NRS 639.070 A REGULATION relating to controlled substances; adding certain substances to the controlled substances listed in Schedule IV; and providing other matters properly relating thereto. Section 1. NAC 453.540 is hereby amended to read as follows: NAC 453.540 Schedule IV. 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • Tools for Optimising Pharmacotherapy in Psychiatry (Therapeutic Drug Monitoring, Molecular Brain Imaging and Pharmacogenetic Tests): Focus on Antidepressants
    The World Journal of Biological Psychiatry ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iwbp20 Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants C. B. Eap, G. Gründer, P. Baumann, N. Ansermot, A. Conca, E. Corruble, S. Crettol, M. L. Dahl, J. de Leon, C. Greiner, O. Howes, E. Kim, R. Lanzenberger, J. H. Meyer, R. Moessner, H. Mulder, D. J. Müller, M. Reis, P. Riederer, H. G. Ruhe, O. Spigset, E. Spina, B. Stegman, W. Steimer, J. Stingl, S. Suzen, H. Uchida, S. Unterecker, F. Vandenberghe & C. Hiemke To cite this article: C. B. Eap, G. Gründer, P. Baumann, N. Ansermot, A. Conca, E. Corruble, S. Crettol, M. L. Dahl, J. de Leon, C. Greiner, O. Howes, E. Kim, R. Lanzenberger, J. H. Meyer, R. Moessner, H. Mulder, D. J. Müller, M. Reis, P. Riederer, H. G. Ruhe, O. Spigset, E. Spina, B. Stegman, W. Steimer, J. Stingl, S. Suzen, H. Uchida, S. Unterecker, F. Vandenberghe & C. Hiemke (2021): Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants, The World Journal of Biological Psychiatry, DOI: 10.1080/15622975.2021.1878427 To link to this article: https://doi.org/10.1080/15622975.2021.1878427 © 2021 The Author(s). Published by Informa Published online: 12 May 2021. UK Limited, trading as Taylor & Francis Group. Submit your article to this journal Article views: 1134 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=iwbp20 THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY https://doi.org/10.1080/15622975.2021.1878427 REVIEW ARTICLE Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants a,b,c,d,eà fà g a h,i j,k C.
    [Show full text]
  • Wo 2009/095395 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 6 August 2009 (06.08.2009) PCT WO 2009/095395 A2 (51) International Patent Classification: Werner [CA/CA], 39 Harper Street, Waterdown, Ontario A61K 9/32 (2006.01) A61K 31/343 (2006.01) LOR 2H3 (CA). XIAOPIN, Jin [CA/CA], 3805 Peri win A61K 9/36 (2006.01) A61K 31/554 (2006.01) kle Crescent, Mississauga, Ontario L5N 6W8 (CA). A61K 31/137 (2006.01) (74) Agent: DUNNE, Sinead, TOMKINS & CO., 5 Dartmouth (21) International Application Number: Road, Dublin 6 (IE). PCT/EP2009/050924 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: 28 January 2009 (28.01.2009) AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (25) Filing Language: English CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, (26) Publication Language: English IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (30) Priority Data: LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, 61/023,951 28 January 2008 (28.01.2008) US MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, (71) Applicant (for all designated States except US): BIO- TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, VAIL LABORATORIES INTERNATIONAL SRL ZW [BB/BB], Welches, Barbados, West Indies, Christ Church 17154 (BB).
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]
  • Benzodiazepines for Anxiety Disorder Treatment When, If Ever, Would I Consider Using Benzodiazepines for Long-Term Treatment of Anxiety Disorders?
    UW PACC Psychiatry and Addictions Case Conference UW Medicine | Psychiatry and Behavioral Sciences BENZODIAZEPINES FOR ANXIETY DISORDER TREATMENT WHEN, IF EVER, WOULD I CONSIDER USING BENZODIAZEPINES FOR LONG-TERM TREATMENT OF ANXIETY DISORDERS? DEB COWLEY MD UNIVERSITY OF WASHINGTON 9/24/20 UW PACC ©2020 University of Washington GENERAL DISCLOSURES The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State. UW PACC ©2020 University of Washington GENERAL DISCLOSURES UW PACC is also supported by Coordinated Care of Washington UW PACC ©2020 University of Washington SPEAKER DISCLOSURES • No conflicts of interest relevant to this topic • Medical Director, PAL for Moms – Weekdays 9-5 – Free – 1-877-725-4666 (PAL4MOM) – [email protected] – Funded by Washington State Health Care Authority UW PACC ©2020 University of Washington PLANNER DISCLOSURES The following series planners have no relevant conflicts of interest to disclose: Mark Duncan MD Cameron Casey Barb McCann PhD Betsy Payn Rick Ries MD Diana Roll Kari Stephens PhD Cara Towle MSN RN Anna Ratzliff MD PhD has received book royalties from John Wiley & Sons (publishers). UW PACC ©2020 University of Washington CASE • A 60 yo woman presents with a long history of generalized anxiety disorder. She also has a history of hypertension and sleep apnea (using CPAP). She has taken benzodiazepines for more than 20 years and is currently on alprazolam 1 mg qid. She does not want to change this medication because she says it has been very helpful and “I don’t know what I would do without it.” She knows she needs it because she becomes very anxious before each dose.
    [Show full text]